telepharmacy & ckd – a making tracks investment strategy · 2017-05-11 · chronic kidney...

24
Telepharmacy & CKD – A Making Tracks Investment Strategy Laura Johnstone Pharmacist Cairns Hospital Renal Unit August 2016

Upload: others

Post on 15-Aug-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Telepharmacy & CKD – A Making Tracks Investment

Strategy Laura Johnstone

Pharmacist Cairns Hospital Renal Unit

August 2016

Page 2: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Outline

• Introduction • Methods • Results • Key Message

Page 3: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

INTRODUCTION

Page 4: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have it

• $32.4 million per year to the health system - 5,000 hospital admissions - 110,000 doctor visits

Page 5: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

CHHHS

TCHHS

Page 6: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Aboriginal and Torres Strait Islander Peoples

• Up to 4 times as likely to have late stage CKD • Those living in remote areas have up to 20

times higher incidence of end-stage renal failure

AND • 30 years younger

Page 7: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Making Tracks Investment Strategy

• Original publication in 2010 “Making Tracks towards closing the gap in health outcomes for Indigenous Queenslanders by 2033” • Launched 2015 - 2018 “Making Tracks investment strategy”

Page 8: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Making Tracks Investment Strategy

‘Preventing ill-health, improving diagnosis and early intervention, and better management and treatment of illness through the use of culturally and clinically effective healthcare.’

Page 9: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Making Tracks Investment Strategy

Priorities • Importance placed on preventative strategies • Multidisciplinary management for minimising

chronic disease • Improvement of health services by

implementing initiatives that increase access

Page 10: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Telepharmacy and CKD

• 3 Queensland Health staff members associated with the role

- Administration Officer - Clinical Nurse - Clinical Pharmacist

Page 11: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Aims of Telepharmacy and CKD • Increase access to a clinical pharmacy service • Contribute to reducing the burden of chronic disease • Deliver individualised and community-based CKD

management education • Improve the prevention, education, early detection

and diagnosis, treatment and self-management of CKD.

• Reduce hospitalisation rates for Aboriginal and Torres Strait Islander people with CKD.

Page 12: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

METHODS

Page 13: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

• Identification

• Appointment scheduled with site

• Appointment letter

• Telehealth Brochure

Page 14: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Telepharmacy Structure • Consent • Introduction • Attendees • Observations • Blood results • Medication review • Survey • Conclusion

Page 15: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Pharmacist documentation

• Integrated Electronic Medication Record (ieMR)

• Software for Specialists (Audit4) • Enterprise wide Liaison Medication System

(eLMS) • Mail/Fax/E-mail to local clinician

Page 16: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

RESULTS

Page 17: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Results • Reporting period January to June 2016 • 129 booked telehealth appointments

• 82 successfully completed • 61% of patients identified as Aboriginal or Torres

Strait Islander

Page 18: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Results

• 667 Pharmacist interventions • Average of 8.1 per patient • 93.9% received education

Page 19: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Interventions Key

Code: Meaning: Code: Meaning:

IWS Indication Without Drug FRD Failed to Receive Drug

DWI Drug Without Indication LAB Inappropriate Lab Monitoring

IDS Improper Drug Selection MRD Medication Record Discrepancy

UD Under therapeutic Dose IE Inadequate Patient Education

OD Over therapeutic Dose IC Inadequate Patient Compliance

ADR Adverse Drug Reaction SI Medication Supply Issues

Page 20: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Results

Intervention: IWS DWI IDS IDI UD OD ADR LAB MRD IE IC

Total: 57 21 17 14 32 28 13 71 322 26 36

Page 21: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Yearly Growth

Year of reporting period OOS Number of Pharmacy Intervention

2015 38 147

2016 82 667

Page 22: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Satisfaction Survey

Page 23: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

Survey Results

56.5%

41.2%

2.4%

Overall Experience:

Very Satisfied:

Satisfied:

Average:

Page 24: Telepharmacy & CKD – A Making Tracks Investment Strategy · 2017-05-11 · Chronic Kidney Disease • 1.7 million Australians affected • 1.5 million don’t even know they have

KEY MESSAGE Telepharmacy is an invaluable health service to prevent CKD progression onto ESRD.

Patients with CKD living in rural and remote areas have a requirement for increased investment to promote awareness and provide education to prevent progression of this silent disease.